Clinical trials on Previously Treated Amyloid Light-chain (AL) Amyloidosis

  • CT-EU-00117867

    Study of JNJ-79635322 for Multiple Myeloma and Amyloidosis

    This study is investigating a new drug called JNJ-79635322, which is a trispecific antibody. The main goal of this study is to establish a recommended dose and schedule of drug administration that will be safe for participants. This medicine is intended for people with relapsed or refractory multiple myeloma or previously treated light chain (AL) amyloidosis.

    In the first part of the study, called dose escalation, doctors will gradually increase the dose of the medicine to find the highest dose that is well tolerated. In the second part, called dose expansion, the medicine will be administered at a previously established dose and doctors will monitor the safety and tolerability of the medicine in different groups of patients.

    JNJ-79635322 will be administered as a subcutaneous injection. During the study, doctors will carefully monitor any side effects and abnormal laboratory test results. The most important thing is to ensure the safety of participants and find the optimal dose of the drug.

    • JNJ-79635322